Hypertension
Conditions
Keywords
treatment-resistant
Brief summary
This study evaluates RAS peptides profiles in patients with treatment resistant arterial hypertension.
Detailed description
Selective quantification of RAS peptides in human plasma triggered investigations evaluating whether RAS peptides could be used as clinical biomarkers in patients receiving antihypertensive treatment. Drug-specific RAS profiles first characterized in healthy normotensive subjects (EKBB 255/12; ClinicalTrials.gov ID NCT01771783) are presently investigated in patients with newly diagnosed arterial hypertension (EKNZ 2015-081; clinicaltrials.gov identifier (ID) NCT02449811). With this observational study RAS peptide profiles will be characterized in patients with treatment resistant hypertension. Data generated by this study will show whether RAS peptide profiles merit further evaluation as clinical biomarkers in this complex patient group.
Interventions
None listed
Sponsors
University Hospital, Basel, Switzerland
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Office blood pressure ≥ 140/90 mmHg and mean 24 hour blood pressure \>130/80 mmHg on average, or \>135/85 mmHg during the day, or \> 120/70 mmHg during the night, despite concurrent use of 3 antihypertensive agents at optimal doses, including one diuretic OR * Office blood pressure and 24 hour mean blood pressure controlled with four or more medications * Age ≥ 18 years * Ability to understand research procedures and to provide written informed consent
Exclusion criteria
* Known secondary arterial hypertension at time of inclusion or diagnosis of secondary hypertension after study inclusion during routine work-up of treatment resistant hypertension * Known obstructive sleep apnea at time of inclusion * History of, or clinically relevant or uncontrolled cardiovascular disease (other than arterial hypertension), namely myocardial infarction within last 3 months or valvular heart disease with clinically relevant reflux or heart failure * Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the research project or compliance with the research plan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RAS peptide concentrations in plasma | baseline, 4h after observed drug intake and steady-state sample |
Secondary
| Measure | Time frame |
|---|---|
| Antihypertensive drug concentrations in plasma | baseline, 4h after observed drug intake and steady-state sample |
Countries
Switzerland
Outcome results
None listed